Profile data is unavailable for this security.
About the company
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
- Revenue in USD (TTM)214.33m
- Net income in USD-121.70m
- Incorporated1999
- Employees700.00
- LocationValneva SE6, Rue Alain BombardSAINT-HERBLAIN 44800FranceFRA
- Phone+33 228073710
- Fax+33 144217078
- Websitehttps://valneva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MiMedx Group Inc | 393.44m | 40.83m | 768.65m | 837.00 | 19.01 | 3.22 | 13.86 | 1.95 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 778.91m | 44.00 | -- | 10.04 | -- | 53.33 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 795.25m | 550.00 | -- | 3.24 | -- | 4.14 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 797.20m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 798.16m | 74.00 | -- | 0.817 | -- | 79.82 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 799.01m | 5.00 | -- | 157.03 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Omeros Corp | 0.00 | -121.24m | 801.18m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Annexon Inc | 0.00 | -208.88m | 813.79m | 99.00 | -- | 4.01 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 821.18m | 55.00 | -- | 2.03 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| Valneva SE (ADR) | 214.33m | -121.70m | 838.37m | 700.00 | -- | 4.64 | -- | 3.91 | -1.38 | -1.38 | 2.58 | 2.09 | 0.3729 | 1.61 | 7.13 | 308,388.70 | -21.18 | -- | -28.97 | -- | 45.36 | -- | -56.78 | -- | 1.36 | -3.61 | 0.5655 | -- | 10.32 | -- | 87.93 | -- | -- | -- |
| Xencor Inc | 167.36m | -138.75m | 851.93m | 250.00 | -- | 1.36 | -- | 5.09 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| Arvinas Inc | 312.30m | -58.50m | 853.54m | 430.00 | -- | 1.67 | -- | 2.73 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 854.28m | -- | 53.51 | 1.33 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 856.24m | 62.00 | -- | 2.65 | -- | 144.71 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 883.01m | 52.00 | -- | 2.87 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 921.83m | 14.00 | -- | 22.32 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Valneva SE's reporting currency: US Dollar USD
0.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| General American Investors Co., Inc. (Investment Management)as of 30 Sep 2025 | 354.36k | 0.41% |
| Wells Fargo Clearing Services LLCas of 30 Sep 2025 | 153.99k | 0.18% |
| Marshall Wace LLPas of 30 Sep 2025 | 31.21k | 0.04% |
| Ironwood Investment Management LLCas of 30 Sep 2025 | 25.14k | 0.03% |
| Morgan Stanley & Co. International Plcas of 30 Sep 2025 | 22.77k | 0.03% |
| Citadel Securities LLCas of 30 Sep 2025 | 16.41k | 0.02% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 10.20k | 0.01% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2025 | 10.18k | 0.01% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2025 | 5.00k | 0.01% |
| GAMMA Investing LLCas of 31 Dec 2025 | 1.86k | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
